All Stories

  1. Key insights from therapeutic drug monitoring in Crohn’s disease patients

    Article • Expert Opinion on Drug Metabolism & Toxicology, April 2019, Taylor & Francis

    Dr Ad A van Bodegraven

  2. Intravenous citrulline generation test to assess intestinal function in intensive care unit patients

    Article • Clinical and Experimental Gastroenterology, April 2017, Dove Medical Press

    Dr Ad A van Bodegraven

  3. Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions

    Article • Inflammatory Bowel Diseases, February 2015, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  4. Allopurinol–thiopurine combination therapy in inflammatory bowel disease

    Article • Clinical Investigation, October 2014, OMICS Publishing Group

    Dr Ad A van Bodegraven

  5. PP081-SUN: Nutritional Status of RCDII and EATL Patients is Poor Compared to Newly Diagnosed Coeliac Disease Patients

    Article • Clinical Nutrition, September 2014, Elsevier

    Dr Ad A van Bodegraven

  6. P-008: Fecal gas analysis by electronic nose: a novel, non-invasive technique for assessment of active and quiescent pediatric inflammatory bowel disease

    Article • Journal of Crohn s and Colitis, September 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  7. Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study

    Article • Journal of Crohn s and Colitis, September 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven, MSc Evelien F.J. de Groot

  8. Limited long-term survival after in-hospital intestinal failure requiring total parenteral nutrition

    Article • American Journal of Clinical Nutrition, August 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  9. Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

    Article • Journal of Crohn s and Colitis, August 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  10. Gonorrhoea of the sigmoid neovagina in a male-to-female transgender

    Article • International Journal of STD & AIDS, July 2014, SAGE Publications

    Dr Ad A van Bodegraven

  11. Rectal Swabs for Analysis of the Intestinal Microbiota

    Article • PLoS ONE, July 2014, PLOS

    Dr Ad A van Bodegraven

  12. Intestinal Vaginoplasty Revisited: A Review of Surgical Techniques, Complications, and Sexual Function

    Article • The Journal of Sexual Medicine, July 2014, Elsevier

    Dr Ad A van Bodegraven

  13. The Scent of Colorectal Cancer: Detection by Volatile Organic Compound Analysis

    Article • Clinical Gastroenterology and Hepatology, July 2014, Elsevier

    Dr Ad A van Bodegraven

  14. Risk factors of work disability in patients with inflammatory bowel disease — A Dutch nationwide web-based survey

    Article • Journal of Crohn s and Colitis, July 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  15. Anorectal complications and function in patients suffering from inflammatory bowel disease: a series of patients with long-term follow-up

    Article • International Journal of Colorectal Disease, June 2014, Springer Science + Business Media

    Dr Ad A van Bodegraven

  16. Su1268 Microbiota Profiling in Children With Functional Constipation

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  17. Sa1985 Short-Term and Long-Term Stability of the Intestinal Microbiota in Healthy Children

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  18. 996 Predicting Mucosal Inflammatory Activity in Crohn's Disease: A New, Validated Non-Endoscopic Disease Activity Index

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  19. Su1890 Comprehensive Nutritional Status of Patients With (Complicated) Celiac Disease and EATL At Presentation

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  20. Mo1185 No Nodular Regenerative Hyperplasia in Sequential Liver Biopsies During Tioguanine Maintenance Therapy in Inflammatory Bowel Disease Patients

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  21. Su1327 Healthcare Costs and Their Predictors in Inflammatory Bowel Disease: Two Year Results From the COIN study

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  22. Su1326 Self-Reported Disability Index in Inflammatory Bowel Disease: Results From a Large Dutch Prospective Cohort

    Article • Gastroenterology, May 2014, Elsevier

    Dr Ad A van Bodegraven

  23. Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, April 2014, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  24. Get the Best Out of Thiopurine Therapy

    Article • Gastroenterology, March 2014, Elsevier

    Dr Ad A van Bodegraven

  25. Authors' response: the role of risedronate in osteopenia in Crohn's disease

    Article • Gut, February 2014, BMJ

    Dr Ad A van Bodegraven

  26. P343 Skewed thiopurine metabolism leads to early therapeutic failure in the majority of patients with inflammatory bowel disease

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  27. P668 Interspace microbiome profiling (IS-pro) enables to differentiate IBD subclasses and disease activity by specific loss of bacterial diversity

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  28. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  29. Maag-, darm- en leverziekten

    Article • January 2014, Springer Science + Business Media

    Dr Ad A van Bodegraven

  30. Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child?

    Article • Expert Review of Gastroenterology & Hepatology, November 2013, Taylor & Francis

    Dr Ad A van Bodegraven

  31. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study

    Article • Journal of Crohn s and Colitis, November 2013, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  32. Neoplasia Yield and Colonoscopic Workload of Surveillance Regimes for Colorectal Cancer in Colitis Patients

    Article • Inflammatory Bowel Diseases, November 2013, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  33. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

    Article • Gut, October 2013, BMJ

    Dr Ad A van Bodegraven

  34. Vitamin and Mineral Deficiencies Are Highly Prevalent in Newly Diagnosed Celiac Disease Patients

    Article • Nutrients, September 2013, MDPI AG

    Dr Ad A van Bodegraven

  35. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study

    Article • International Journal of Cancer, September 2013, Wiley

    Dr Ad A van Bodegraven

  36. Case on Short Bowel Syndrome

    Article • August 2013, Springer Science + Business Media

    Dr Ad A van Bodegraven

  37. Case on Recurrence of Crohn’s Disease

    Article • August 2013, Springer Science + Business Media

    Dr Ad A van Bodegraven

  38. Reply

    Article • Clinical Gastroenterology and Hepatology, August 2013, Elsevier

    Dr Ad A van Bodegraven

  39. Thiopurine treatment in patients with Crohn's disease leads to a selective reduction of an effector cytotoxic gene expression signature revealed by whole-genome expression profiling

    Article • Molecular Immunology, July 2013, Elsevier

    Dr Ad A van Bodegraven

  40. Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents

    Article • Clinical Gastroenterology and Hepatology, July 2013, Elsevier

    Dr Ad A van Bodegraven

  41. Sustained Clinical Benefit and Tolerability of Methotrexate Monotherapy After Thiopurine Therapy in Patients With Crohn's Disease

    Article • Clinical Gastroenterology and Hepatology, June 2013, Elsevier

    Dr Ad A van Bodegraven

  42. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation

    Article • Journal of Crohn s and Colitis, June 2013, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  43. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease

    Article • Alimentary Pharmacology & Therapeutics, May 2013, Wiley

    Dr Ad A van Bodegraven

  44. Bomb calorimetry, the gold standard for assessment of intestinal absorption capacity: normative values in healthy ambulant adults

    Article • Journal of Human Nutrition and Dietetics, May 2013, Wiley

    Dr Ad A van Bodegraven

  45. Ten Years of Infliximab for Crohn’s Disease

    Article • Inflammatory Bowel Diseases, April 2013, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  46. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

    Article • Gut, March 2013, BMJ

    Dr Ad A van Bodegraven

  47. Safe Use of Allopurinol and Low-dose Mercaptopurine Therapy During Pregnancy in an Ulcerative Colitis Patient

    Article • Inflammatory Bowel Diseases, March 2013, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  48. Ulcerative colitis: clinical course and complications

    Article • March 2013, Future Medicine

    Dr Ad A van Bodegraven

  49. Allopurinol in Subjects with Colorectal Adenoma--Letter

    Article • Cancer Prevention Research, February 2013, American Association for Cancer Research (AACR)

    Dr Ad A van Bodegraven

  50. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease

    Article • Gut, February 2013, BMJ

    Dr Ad A van Bodegraven

  51. Oxidation-Mediated DNA Crosslinking Contributes to Toxicity of 6-Thioguanine in Human Cells -- Letter

    Article • Cancer Research, February 2013, American Association for Cancer Research (AACR)

    Dr Ad A van Bodegraven

  52. P433 Mercaptopurine therapy in IBD patients modulates GTPase Rac1

    Article • Journal of Crohn s and Colitis, February 2013, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  53. Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, February 2013, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  54. P110 Surveillance for colorectal cancer in colitis patients: effect of the implementation of new British and American guidelines on neoplasia yield

    Article • Journal of Crohn s and Colitis, February 2013, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  55. Adenomas in Patients with Inflammatory Bowel Disease Are Associated with an Increased Risk of Advanced Neoplasia

    Article • Inflammatory Bowel Diseases, February 2013, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  56. Idiopathische chronische darmontstekingen

    Article • January 2013, Springer Science + Business Media

    Dr Ad A van Bodegraven

  57. Voeding bij dikkedarmaandoeningen

    Article • January 2013, Springer Science + Business Media

    Dr Ad A van Bodegraven

  58. Geneesmiddelen bij chronische idiopathische darmontstekingen (IBD)

    Article • January 2013, Springer Science + Business Media

    Dr Ad A van Bodegraven

  59. Words that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behavior

    Article • Patient Preference and Adherence, December 2012, Taylor & Francis

    Dr Ad A van Bodegraven

  60. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

    Article • Gut, November 2012, BMJ

    Dr Ad A van Bodegraven

  61. Defective IL-1A expression in patients with Crohn’s disease is related to attenuated MAP3K4 signaling

    Article • Human Immunology, September 2012, Elsevier

    Dr Ad A van Bodegraven

  62. Commentary: tioguanine in the treatment of refractory coeliac disease - authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, August 2012, Wiley

    Dr Ad A van Bodegraven

  63. Tioguanine in the treatment of refractory coeliac disease - a single centre experience

    Article • Alimentary Pharmacology & Therapeutics, May 2012, Wiley

    Dr Ad A van Bodegraven

  64. Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation

    Article • Journal of Cellular Biochemistry, May 2012, Wiley

    Dr Ad A van Bodegraven

  65. Letter: thiopurines during pregnancy and intrauterine exposure to metabolites

    Article • Alimentary Pharmacology & Therapeutics, March 2012, Wiley

    Dr Ad A van Bodegraven

  66. P385 Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant inflammatory bowel disease patients

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  67. OP16 Adding ciprofloxacin to adalimumab results in a higher fistula closure rate in perianal fistulizing Crohn's disease

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  68. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  69. OP14 Adenomas in patients with inflammatory bowel disease: Increased risk of advanced neoplasia

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  70. OP09 Anti TNF-α therapy is a major cost driver in inflammatory bowel disease: Results from the COIN study

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  71. P194 Is there a difference in quality of life or costs between ulcerative colitis patients with a pouch or an ileostomy?

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  72. Intrauterine exposure to thiopurines

    Article • Reproductive Toxicology, January 2012, Elsevier

    Dr Ad A van Bodegraven

  73. Faculty Opinions recommendation of Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma.

    Article • December 2011, F1000Research

    Dr Ad A van Bodegraven

  74. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for crohn's disease-associated bone loss

    Article • Journal of Cellular Biochemistry, December 2011, Wiley

    Dr Ad A van Bodegraven

  75. Allopurinol Enhances the Activity of Hypoxanthine-Guanine Phosphoribosyltransferase in Inflammatory Bowel Disease Patients During Low-Dose Thiopurine Therapy: Preliminary Data of an Ongoing Series

    Article • Nucleosides Nucleotides & Nucleic Acids, December 2011, Taylor & Francis

    Dr Ad A van Bodegraven

  76. Differential association of two PTPN22 coding variants with Crohnʼs disease and ulcerative colitis

    Article • Inflammatory Bowel Diseases, November 2011, Wolters Kluwer Health

    Dr Ad A van Bodegraven, MD. PhD. Carlos Taxonera

  77. Thiopurine metabolite measurement - not for everyone

    Article • Alimentary Pharmacology & Therapeutics, September 2011, Wiley

    Dr Ad A van Bodegraven

  78. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study

    Article • Inflammatory Bowel Diseases, September 2011, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  79. Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease

    Article • PLoS ONE, August 2011, PLOS

    Dr Ad A van Bodegraven

  80. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine

    Article • British Journal of Pharmacology, May 2011, Wiley

    Professor Godefridus J Peters, Dr Ad A van Bodegraven

  81. Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis

    Article • BMC Gastroenterology, May 2011, Springer Science + Business Media

    Dr Ad A van Bodegraven

  82. Misclassification of dysplasia in patients with inflammatory bowel disease

    Article • Inflammatory Bowel Diseases, May 2011, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  83. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease—Proceedings of the first Thiopurine Task Force meeting

    Article • Digestive and Liver Disease, April 2011, Elsevier

    Dr Ad A van Bodegraven

  84. Assessment of Small Bowel Function in Critical Illness: Potential Role of Citrulline Metabolism

    Article • Journal of Intensive Care Medicine, March 2011, SAGE Publications

    Dr Ad A van Bodegraven

  85. Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands

    Article • Scandinavian Journal of Gastroenterology, February 2011, Taylor & Francis

    Dr Ad A van Bodegraven

  86. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis

    Article • Digestive and Liver Disease, February 2011, Elsevier

    Dr Ad A van Bodegraven

  87. Maag-, darm- en leverziekten

    Article • January 2011, Springer Science + Business Media

    Dr Ad A van Bodegraven

  88. Malabsorption and nutritional balance in the ICU: fecal weight as a biomarker: a prospective observational pilot study

    Article • Critical Care, January 2011, Springer Science + Business Media

    Dr Ad A van Bodegraven

  89. Histomorphometric Analysis Reveals Reduced Bone Mass and Bone Formation in Patients With Quiescent Crohn's Disease

    Article • Gastroenterology, January 2011, Elsevier

    Dr Ad A van Bodegraven

  90. Faculty Opinions recommendation of Total enteral nutrition in prevention of pancreatic necrotic infection in severe acute pancreatitis.

    Article • December 2010, F1000Research

    Dr Ad A van Bodegraven

  91. Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations†

    Article • Inflammatory Bowel Diseases, December 2010, Wolters Kluwer Health

    Dr Ad A van Bodegraven, Prof. Luis Rodrigo

  92. Differential association of two PTPN22 coding variants with Crohn’s disease and ulcerative colitis

    Article • Journal of Translational Medicine, November 2010, Springer Science + Business Media

    Dr Ad A van Bodegraven

  93. ECCO consensus: Evidence-based use of 6-thioguanine therapy in Crohn's disease?

    Article • Journal of Crohn s and Colitis, October 2010, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  94. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohnʼs disease†

    Article • Inflammatory Bowel Diseases, October 2010, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  95. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts

    Article • Inflammatory Bowel Diseases, September 2010, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  96. Antibodies in Patients with Ankylosing Spondylitis without Inflammatory Bowel Disease

    Article • The Journal of Rheumatology, September 2010, The Journal of Rheumatology

    Dr Ad A van Bodegraven, Hana Ratnawati

  97. IS‐pro: high‐throughput molecular fingerprinting of the intestinal microbiota

    Article • The FASEB Journal, July 2010, Wiley

    Dr Ad A van Bodegraven

  98. Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn's disease

    Article • Human Molecular Genetics, July 2010, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  99. Limited Intra-Individual Variability in Hypoxanthine-Guanine Phosphoribosyl Transferase, Thiopurine S-Methyl Transferase, and Xanthine Oxidase Activity in Inflammatory Bowel Disease Patients During 6-Thioguanine Therapy

    Article • Nucleosides Nucleotides & Nucleic Acids, June 2010, Taylor & Francis

    Dr Ad A van Bodegraven

  100. Faculty Opinions recommendation of Effects of chronic metabolic acidosis on splanchnic protein turnover and oxygen consumption in human beings.

    Article • June 2010, F1000Research

    Dr Ad A van Bodegraven

  101. Limited stability of thiopurine metabolites in blood samples: Relevant in research and clinical practise

    Article • Journal of Chromatography B, June 2010, Elsevier

    Dr Ad A van Bodegraven

  102. W1209 Azathioprine or 6-Mercaptopurine Associated Hepatotoxicity Diminishes Upon Administration of 6-Thioguanine in IBD Patients

    Article • Gastroenterology, May 2010, Elsevier

    Dr Ad A van Bodegraven

  103. W1820 Universal Duodenal Microbiota With Is-Pro in Individuals Undergoing Routine Gastroscopy

    Article • Gastroenterology, May 2010, Elsevier

    Dr Ad A van Bodegraven, Dries Budding

  104. M2003 Low Inter-Observer Agreement on Nodular Regenerative Hyperplasia of the Liver: An European Inter-Observer Analysis

    Article • Gastroenterology, May 2010, Elsevier

    Dr Ad A van Bodegraven

  105. 415 Liver Histology of IBD Patients Who are Treated With 6-Thioguanine Due to Failure of Conventional Thiopurines Reveals Very Few Cases of Nodular Regenerative Hyperplasia

    Article • Gastroenterology, May 2010, Elsevier

    Dr Ad A van Bodegraven

  106. 250 Substantial Increase of Progression Rate of Flat Low-Grade Dysplasia in Inflammatory Bowel Disease After Review by an Expert Pathologist Panel

    Article • Gastroenterology, May 2010, Elsevier

    Dr Ad A van Bodegraven

  107. Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon

    Article • Alimentary Pharmacology & Therapeutics, March 2010, Wiley

    Dr Ad A van Bodegraven

  108. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy

    Article • British Journal of Pharmacology, March 2010, Wiley

    Dr Ad A van Bodegraven

  109. Erratum: Corrigendum: Genetic Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk

    Article • The American Journal of Gastroenterology, February 2010, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  110. Distribution of peroxisome proliferator–activated receptor–gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease

    Article • Inflammatory Bowel Diseases, February 2010, Wolters Kluwer Health

    Dr Ad A van Bodegraven, Umid Shrestha

  111. Diagnosing malabsorption in the intensive care unit

    Article • F1000 Medicine Reports, January 2010, F1000Research

    Dr Ad A van Bodegraven

  112. Genomic Assessment of Inflammatory Bowel Disease

    Article • January 2010, Elsevier

    Dr Ad A van Bodegraven

  113. Maag-, darm- en leverziekten

    Article • January 2010, Springer Science + Business Media

    Dr Ad A van Bodegraven

  114. PP022 DIAGNOSTIC ACCURACY OF FECAL WEIGHT TO IDENTIFY CLINICAL SIGNIFICANT MALABSORPTION IN CRITICALLY ILL PATIENTS

    Article • Clinical Nutrition Supplements, January 2010, Elsevier

    Dr Ad A van Bodegraven

  115. PP023 ICU MALABSORPTION SYNDROME CHARACTERISTICS: FECAL ENERGY AND MACRONUTRIENT LOSSES

    Article • Clinical Nutrition Supplements, January 2010, Elsevier

    Dr Ad A van Bodegraven

  116. PP021 INTRAVENOUS GLUTAMINE ADMINISTRATION IS THE PREFERRED ROUTE FOR THE CITRULLINE GENERATION TEST IN STABLE ICU PATIENTS

    Article • Clinical Nutrition Supplements, January 2010, Elsevier

    Dr Ad A van Bodegraven

  117. Genetic Association Analysis of the Functional c.714T>G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease

    Article • PLoS ONE, November 2009, PLOS

    Dr Ad A van Bodegraven

  118. On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance

    Article • Current Drug Metabolism, November 2009, Bentham Science Publishers

    Dr Ad A van Bodegraven

  119. Genetic Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk

    Article • The American Journal of Gastroenterology, October 2009, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  120. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis

    Article • Inflammatory Bowel Diseases, September 2009, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  121. On the malignant potential of thiopurine therapy

    Article • Blood, June 2009, American Society of Hematology

    Dr Ad A van Bodegraven

  122. Effect of inflammatory cytokines on the differentiation of primary human bone cells in patients with crohn's disease

    Article • Bone, June 2009, Elsevier

    Dr Ad A van Bodegraven

  123. 667 Temporal Stability of Faecal Microbiota By Inter Spacer rDNA Bacterial Profiling (IS-pro)

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven, Dries Budding

  124. M1107 Regional Stability of Intestinal Microbiota with Inter Spacer Bacterial Profiling (IS-pro)

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven, Dries Budding

  125. M1108 Fingerprinting the Human Gut Microbiome: Evaluation of a Terminal Restriction Fragment Length Polymorphism (T-RFLP) Kit On Human Gastrointestinal Biopsies

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  126. W1110 6-Thioguanine Induces Remission and Mucosal Healing in IBD

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  127. S1031 Increased Risk of Lymphoma Among Inflammatory Bowel Disease Patients Treated with Azathioprine in a Dutch Nationwide Study

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  128. W1099 Adequately Dosed 6-Thioguanine Is a Well Tolerated and Safe Rescue Drug in Azathioprine or 6-Mercaptopurine Intolerant IBD Patients

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  129. W1640 Detection of Tropheryma Whipplei DNA in Intestinal Biopsy Specimens with a Novel Real-Time PCR

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  130. 204 Genetic and Mucosal Expression Analysis Shows Important Roles for JAK2 and MST1 in the Pathogenesis of Ulcerative Colitis and Identifies More Susceptibility Loci

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  131. S1191 The Pattern Recognition Receptor Dectin-1 Is Up-Regulated in Active Inflammatory Bowel Disease Without An Association with a Potentially Explanatory Non-Synonymous Polymorphism Within Dectin-1

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  132. S1172 The Differential Association of the FcgR2a and FcgR3a Genes in Inflammatory Bowel Diseases Across Three Caucasian Populations

    Article • Gastroenterology, May 2009, Elsevier

    Dr Ad A van Bodegraven

  133. Faculty Opinions recommendation of Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages.

    Article • April 2009, F1000Research

    Dr Ad A van Bodegraven

  134. Post-Colonoscopy Massive Air Leakage With Full Body Involvement: An Impressive Complication With Uneventful Recovery

    Article • The American Journal of Gastroenterology, April 2009, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  135. Faculty Opinions recommendation of Determining small intestinal transit time and pathomorphology in critically ill patients using video capsule technology.

    Article • February 2009, F1000Research

    Dr Ad A van Bodegraven

  136. 6 - Temporal stability of faecal microbiota by Inter Spacer rDNA bacterial profiling (IS-pro)

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  137. Local application of tacrolimus in distal colitis: Feasible and safe

    Article • Inflammatory Bowel Diseases, February 2009, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  138. Inflammatory Bowel Disease

    Article • January 2009, Elsevier

    Dr Ad A van Bodegraven

  139. Leukopenia due to Parvovirus B19 in a Crohn's Disease Patient Using Azathioprine

    Article • Digestion, January 2009, Karger Publishers

    Dr Ad A van Bodegraven

  140. Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial influence on microbiota and gastrointestinal quality of life

    Article • Scandinavian Journal of Gastroenterology, January 2009, Taylor & Francis

    Dr Ad A van Bodegraven

  141. P109 QUANTIFICATION OF INTESTINAL ABSORPTION CAPACITY IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE OF THE DIGESTIVE TRACT

    Article • Clinical Nutrition Supplements, January 2009, Elsevier

    Dr Ad A van Bodegraven

  142. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort

    Article • Gut, September 2008, BMJ

    Dr Ad A van Bodegraven

  143. Vertebral deformities and inflammatory bowel disease

    Article • European Journal of Gastroenterology & Hepatology, September 2008, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  144. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial)

    Article • BMC Surgery, August 2008, Springer Science + Business Media

    Dr Ad A van Bodegraven

  145. Low and adequately dosed 6-thioguanine: Not so bad after all

    Article • Inflammatory Bowel Diseases, August 2008, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  146. Paradoxical Elevated Thiopurine S-Methyltransferase Activity After Pancytopenia During Azathioprine Therapy: Potential Influence of Red Blood Cell Age

    Article • Therapeutic Drug Monitoring, June 2008, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  147. Letters to the Editor

    Article • Journal of Parenteral and Enteral Nutrition, May 2008, Wiley

    Dr Ad A van Bodegraven

  148. Genetic Analysis of Innate Immunity in Crohn's Disease and Ulcerative Colitis Identifies Two Susceptibility Loci Harboring CARD9 and IL18RAP

    Article • The American Journal of Human Genetics, May 2008, Elsevier

    Dr Ad A van Bodegraven

  149. T1245 The Effect of NOD2 Activation On TLR2 Mediated Cytokine Responses Is Dependent On Activation Dose and NOD2 Genotype

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  150. 503 Alteration of Thiopurinephosphate Metabolite Levels By Aminosalicylates in IBD-Patients

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  151. S1231 Predictors for Failing Thiopurine Therapy in IBD Patients; Treated At An Academic or General District Hospital

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  152. S1238 Levels of 6-Thioguanine Nucleotides Following Oral and Intravenous Administration of Relatively Low-Dosed 6-TG (0,3 mg/kg) in IBD-Patients

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  153. M2077 Evidence for Genetic Heterogeneity in Dutch Caucasian and Spanish Galician Crohn's Disease Patients

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  154. 502 Thiopurine Metabolite Measurements During Pregnancy in Mother and Child

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  155. M2073 NOD2/CARD15, Toll-Like Receptor 4, and Toll-Like Receptor 9 Gene Polymorphisms in Spanish and Dutch Patients with Inflammatory Bowel Disease

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  156. 493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

    Article • Gastroenterology, April 2008, Elsevier

    Dr Ad A van Bodegraven

  157. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype

    Article • Genes and Immunity, March 2008, Springer Science + Business Media

    Dr Ad A van Bodegraven

  158. High frequency of early colorectal cancer in inflammatory bowel disease

    Article • Gut, March 2008, BMJ

    Dr Ad A van Bodegraven

  159. The citrulline generation test: proposal for a new enterocyte function test

    Article • Alimentary Pharmacology & Therapeutics, March 2008, Wiley

    Dr Ad A van Bodegraven

  160. P090 THIOPURINE METABOLITE MEASUREMENTS DURING PREGNANCY IN MOTHER AND CHILD

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  161. P107 PREDICTORS FOR FAILING THIOPURINE THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS; TREATED AT AN ACADEMIC OR GENERAL DISTRICT HOSPITAL

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  162. P151 LEVELS OF 6-THIOGUANINE NUCLEOTIDES FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION OF RELATIVELY LOW-DOSED 6-TG (0, 3 MG/KG) IN INFLAMMATORY BOWEL DISEASE PATIENTS

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  163. P178 THE EFFECTIVENESS OF THIOPURINE THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IN AN ACADEMIC AND GENERAL DISTRICT HOSPITAL SETTING

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  164. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients

    Article • Digestive and Liver Disease, February 2008, Elsevier

    Dr Ad A van Bodegraven

  165. P221 NOD2/CARD15, TOLL-LIKE RECEPTOR 4, AND TOLL-LIKE RECEPTOR 9 GENE POLYMORPHISMS IN SPANISH AND DUTCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  166. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

    Article • The Lancet, February 2008, Elsevier

    Dr Ad A van Bodegraven

  167. Stability of Thiopurine Metabolites: A Potential Analytical Bias

    Article • Clinical Chemistry, January 2008, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  168. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: Prevalence of nodular regenerative hyperplasia

    Article • Scandinavian Journal of Gastroenterology, January 2008, Taylor & Francis

    Dr Ad A van Bodegraven

  169. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitisAn unusual case of ascites

    Article • Gut, December 2007, BMJ

    Dr Ad A van Bodegraven

  170. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD

    Article • Nature Clinical Practice Gastroenterology &#38 Hepatology, December 2007, Springer Science + Business Media

    Dr Ad A van Bodegraven

  171. Poor Diagnostic Accuracy of a Single Fasting Plasma Citrulline Concentration to Assess Intestinal Energy Absorption Capacity

    Article • The American Journal of Gastroenterology, December 2007, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  172. Dose-Dependent Influence of 5-Aminosalicylates on Thiopurine Metabolism

    Article • The American Journal of Gastroenterology, December 2007, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  173. The Value of Double-Balloon Enteroscopy in Patients With Refractory Celiac Disease

    Article • The American Journal of Gastroenterology, May 2007, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  174. P073 ADEQUATELY DOSED 6-TG USE IN CHRONIC INTESTINAL INFLAMMATION IS NOT ASSOCIATED WITH NODULAR REGENERATIVE HYPERPLASIA: A SERIES OF 73 LIVER BIOPSIES

    Article • Journal of Crohn s and Colitis Supplements, March 2007, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  175. P075 CHEMICAL STABILITY OF THIOPURINE METABOLITES IN ERYTHROCYTES DURING 6-MERCAPTOPURINE AND AZATHIOPRINE TREATMENT

    Article • Journal of Crohn s and Colitis Supplements, March 2007, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  176. P109 DOSE-DEPENDENT INFLUENCE OF 5-ASA ON THIOPURINE METABOLISM

    Article • Journal of Crohn s and Colitis Supplements, March 2007, Oxford University Press (OUP)

    Dr Ad A van Bodegraven

  177. Extended Thiopurine Metabolite Assessment During 6-Thioguanine Therapy for Immunomodulation in Crohn's Disease

    Article • The Journal of Clinical Pharmacology, February 2007, Wiley

    Dr Ad A van Bodegraven

  178. Genetic Variation in Myosin IXB Is Associated With Ulcerative Colitis

    Article • Gastroenterology, December 2006, Elsevier

    Dr Ad A van Bodegraven

  179. Azathioprine Use During Pregnancy: Unexpected Intrauterine Exposure to Metabolites

    Article • The American Journal of Gastroenterology, June 2006, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  180. Are malnourished patients complex patients? Health status and care complexity of malnourished patients detected by the Short Nutritional Assessment Questionnaire (SNAQ)

    Article • European Journal of Internal Medicine, May 2006, Elsevier

    Dr Ad A van Bodegraven

  181. Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice

    Article • Alimentary Pharmacology & Therapeutics, April 2006, Wiley

    Dr Ad A van Bodegraven

  182. A Prospective Study Comparing Video Capsule Endoscopy with Double-Balloon Enteroscopy in Patients with Obscure Gastrointestinal Bleeding

    Article • The American Journal of Gastroenterology, January 2006, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  183. 6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working Party

    Article • Digestion, January 2006, Karger Publishers

    Dr Ad A van Bodegraven

  184. The Toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localization of Crohn??s disease, without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway.

    Article • European Journal of Gastroenterology & Hepatology, January 2006, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  185. PCR results of Saccaromyces cerevisiae in intestinal mucosal samples of patients with IBD

    Article • European Journal of Gastroenterology & Hepatology, January 2006, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  186. A prospective study comparing video capsule endoscopy followed by double balloon enteroscopy for suspected small bowel disease

    Article • European Journal of Gastroenterology & Hepatology, January 2006, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  187. Double balloon enteroscopy in Peutz Jeghers disease: first experience with a new diagnostic and therapeutic tool

    Article • European Journal of Gastroenterology & Hepatology, January 2006, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  188. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis

    Article • International Journal of Immunogenetics, December 2005, Wiley

    Dr Ad A van Bodegraven

  189. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment

    Article • Alimentary Pharmacology & Therapeutics, September 2005, Wiley

    Dr Ad A van Bodegraven

  190. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: A pilot study

    Article • Drugs of Today, January 2005, Prous Science

    Dr Ad A van Bodegraven

  191. Nodular regenerative hyperplasia and thiopurines: The case for level-dependent toxicity

    Article • Liver Transplantation, January 2005, Wiley

    Dr Ad A van Bodegraven

  192. 6-Thioguanine for Crohn's disease during pregnancy: Thiopurine metabolite measurements in both mother and child

    Article • Scandinavian Journal of Gastroenterology, January 2005, Taylor & Francis

    Dr Ad A van Bodegraven

  193. Hand-Assisted Laparoscopic Versus Open Restorative Proctocolectomy With Ileal Pouch Anal Anastomosis

    Article • Annals of Surgery, December 2004, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  194. Haemostasis in inflammatory bowel diseases: clinical relevance

    Article • Scandinavian Journal of Gastroenterology, December 2003, Taylor & Francis

    Dr Ad A van Bodegraven

  195. Treatment of extraintestinal manifestations in inflammatory bowel disease

    Article • Current Treatment Options in Gastroenterology, June 2003, Springer Science + Business Media

    Dr Ad A van Bodegraven

  196. A functional single nucleotide polymorphism of the Tlr4 gene is correlated with Crohn's disease but not with ulcerative colitis

    Article • Gastroenterology, April 2003, Elsevier

    Dr Ad A van Bodegraven

  197. Nod2 is expressed by myeloid blood dendritic cells, mature Nod2 mutant and wild-type blood dendritic cells induce similar T-cell phenotypes

    Article • Gastroenterology, April 2003, Elsevier

    Dr Ad A van Bodegraven

  198. Signal transducer and activator of transcription 6 gene G2964A polymorphism and inflammatory bowel disease

    Article • Clinical & Experimental Immunology, February 2003, Wiley

    Dr Ad A van Bodegraven

  199. Alternative approach to massive gastrointestinal bleeding in ulcerative colitis

    Article • European Journal of Gastroenterology & Hepatology, February 2003, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  200. Cheilitis Granulomatosa and Optic Neuropathy as Rare Extraintestinal Manifestations of Crohn's Disease

    Article • Journal of Clinical Gastroenterology, May 2002, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  201. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis

    Article • European Journal of Gastroenterology & Hepatology, April 2002, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  202. Endosonographic Evidence of Persistence of Crohnʼs Disease-Associated Fistulas After Infliximab Treatment, Irrespective of Clinical Response

    Article • Diseases of the Colon & Rectum, January 2002, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  203. CTLA4 Gene Polymorphisms in Dutch and Chinese Patients with Inflammatory Bowel Disease

    Article • Scandinavian Journal of Gastroenterology, January 2002, Taylor & Francis

    Dr Ad A van Bodegraven

  204. Lipoprotein (a), thrombophilia and inflammatory bowel disease

    Article • European Journal of Gastroenterology & Hepatology, December 2001, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  205. Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage

    Article • Clinical Immunology, August 2001, Elsevier

    Dr Ad A van Bodegraven

  206. Extraintestinal complications of inflammatory bowel disease

    Article • Current Treatment Options in Gastroenterology, June 2001, Springer Science + Business Media

    Dr Ad A van Bodegraven

  207. Hemostatic imbalance in active and quiescent ulcerative colitis

    Article • The American Journal of Gastroenterology, February 2001, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  208. Hemostatic imbalance in active and quiescent ulcerative colitis

    Article • The American Journal of Gastroenterology, February 2001, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  209. Infliximab for treatment of perineal metastatic Crohn's disease

    Article • Gastroenterology, April 2000, Elsevier

    Dr Ad A van Bodegraven

  210. Efficacy and safety of infliximab treatment for refractory and fistulizing Crohn's disease in a dutch expanded access program

    Article • Gastroenterology, April 2000, Elsevier

    Dr Ad A van Bodegraven

  211. Activation of coagulation and fibrinolysis resulting in a hemostatic imbalance in the treatment of active ulcerative colitis

    Article • Gastroenterology, April 2000, Elsevier

    Dr Ad A van Bodegraven

  212. Serum Eosinophil Cationic Protein in Active and Quiescent Ulcerative Colitis

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2000, De Gruyter

    Dr Ad A van Bodegraven

  213. Esophagopleural fistula treated endoscopically with argon beam electrocoagulation and clips

    Article • Gastrointestinal Endoscopy, September 1999, Elsevier

    Dr Ad A van Bodegraven

  214. Hyper immunoglobulin-D syndrome

    Article • European Journal of Gastroenterology & Hepatology, December 1998, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  215. Hypercoagulation in clinically active and quiescent ulcerative colitis

    Article • European Journal of Gastroenterology & Hepatology, December 1998, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  216. Addition of Low-Dose Oral Cyclosporine in Severe Ulcerative Colitis-Pharmacokinetics and Clinical Outcome Report of Twelve Cases

    Article • Journal of Clinical Gastroenterology, July 1998, Wolters Kluwer Health

    Dr Ad A van Bodegraven

  217. Serum eosinophil cationic protein in active and quiescent ulcerative colitis

    Article • Gastroenterology, April 1998, Elsevier

    Dr Ad A van Bodegraven

  218. Hypercoagulation in clinically active and quiescent ulcerative colitis

    Article • Gastroenterology, April 1998, Elsevier

    Dr Ad A van Bodegraven

  219. The relation between coagulation, fibrinolysis and factor XIII levels in ulcerative colitis

    Article • Gastroenterology, April 1998, Elsevier

    Dr Ad A van Bodegraven

  220. Gallbladder Contents and Fasting Gallbladder Volumes during and after Pregnancy

    Article • Scandinavian Journal of Gastroenterology, January 1998, Taylor & Francis

    Dr Ad A van Bodegraven

  221. Distribution of mesalazine enemas in active and quiescent ulcerative colitis.

    Article • Alimentary Pharmacology & Therapeutics, June 1996, Wiley

    Dr Ad A van Bodegraven

  222. Fibrinolytic Split Products, Fibrinolysis, and Factor XIII Activity in Inflammatory Bowel Disease

    Article • Scandinavian Journal of Gastroenterology, January 1995, Taylor & Francis

    Dr Ad A van Bodegraven